The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

On October 2, 2024, the U.S. Food and Drug Administration (FDA) determined the shortage of the tirzepatide injection, a glucagon-like peptide ...

The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.

The drug uses the active ingredient tirzepatide and was approved by the FDA in May 2022 for type 2 diabetes; although McCaskill said her blood sugar was elevated, she didn’t have diabetes ...

The FDA placed tirzepatide on its drug shortage list in December of 2022—and that's where it remained until last week. On October 2, the FDA announced that the tirzepatide shortage had been ...